Eli Lilly completed a phase 3 trial for its weight loss drug, orforglipron, which showed promising results in evaluating its safety and efficacy for adults with Type 2 diabetes and inadequate glycemic control.
The once-daily oral GLP-1 receptor agonist significantly reduced blood sugar and body weight in adults with Type 2 diabetes and had a safety profile consistent with injectable therapies, according to an April 17 news release from the drugmaker.
In the trial, orforglipron lowered average A1C levels by 1.3% to 1.6% and led to weight loss of up to 16 pounds at the highest dose over 40 weeks. More than 65% of participants reached an A1C level below 6.5%.
Orforglipron is the first small-molecule GLP-1 therapy to successfully complete a phase 3 trial. Eli Lilly plans to submit for regulatory approval for weight management by the end of 2025 and for Type 2 diabetes in 2026.
